AR118202A1 - Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos - Google Patents

Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos

Info

Publication number
AR118202A1
AR118202A1 ARP200100536A ARP200100536A AR118202A1 AR 118202 A1 AR118202 A1 AR 118202A1 AR P200100536 A ARP200100536 A AR P200100536A AR P200100536 A ARP200100536 A AR P200100536A AR 118202 A1 AR118202 A1 AR 118202A1
Authority
AR
Argentina
Prior art keywords
influenza
live attenuated
virus
equine
influenza virus
Prior art date
Application number
ARP200100536A
Other languages
English (en)
Original Assignee
Univ Rochester
Univ Kentucky Res Found
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Univ Kentucky Res Found, Zoetis Services Llc filed Critical Univ Rochester
Publication of AR118202A1 publication Critical patent/AR118202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente proporciona composiciones y métodos relacionados con vacunas contra la influenza equina de virus vivos atenuados. En un aspecto, la presente se refiere a una composición que comprende una vacuna multivalente contra la influenza equina de virus vivos atenuados, que comprende un primer virus de la influenza vivo atenuado que expresa uno o más antígenos de un virus de influenza equina H3N8 clado 1; y un segundo virus de influenza vivo atenuado que expresa uno o más antígenos de un virus de influenza equina H3N8 clado 2, en donde el segundo virus de influenza vivo atenuado expresa HA, NA, o una de sus combinaciones de A / equino / Lancashire / 1 / 2016 H3N8.
ARP200100536A 2019-02-27 2020-02-27 Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos AR118202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962811112P 2019-02-27 2019-02-27

Publications (1)

Publication Number Publication Date
AR118202A1 true AR118202A1 (es) 2021-09-22

Family

ID=70005787

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100536A AR118202A1 (es) 2019-02-27 2020-02-27 Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos

Country Status (8)

Country Link
US (1) US20220133877A1 (es)
EP (1) EP3930749A1 (es)
CN (1) CN113905759A (es)
AR (1) AR118202A1 (es)
BR (1) BR112021016182A2 (es)
CA (1) CA3130781A1 (es)
MX (1) MX2021010343A (es)
WO (1) WO2020176709A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
EP0702085B2 (en) 1994-07-18 2010-01-13 Conzelmann, Karl-Klaus, Prof. Dr. Recombinant infectious non-segmented negative strand RNA virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DK0780475T4 (da) 1995-08-09 2006-10-23 Schweiz Serum & Impfinst Fremgangsmåde til fremstilling af infektiöse negativ-streng RNA-virus
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
AU3799797A (en) 1996-07-15 1998-02-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
EP0932684A2 (en) 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
WO1999002657A1 (en) 1997-07-11 1999-01-21 Yale University Rhabdoviruses with reengineered coats
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
AU2002365244B2 (en) 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
WO2017210528A1 (en) * 2016-06-03 2017-12-07 University Of Rochester Equine influenza virus live-attenuated vaccines

Also Published As

Publication number Publication date
US20220133877A1 (en) 2022-05-05
CN113905759A (zh) 2022-01-07
CA3130781A1 (en) 2020-09-03
BR112021016182A2 (pt) 2021-11-03
EP3930749A1 (en) 2022-01-05
MX2021010343A (es) 2022-01-18
WO2020176709A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
CO2017004119A2 (es) Partículas tipo virus modificadas de cmv
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
BR112014013276A2 (pt) vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112021001188A8 (pt) Composição que contém vacina contra a influenza
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
CO2021001926A2 (es) Composiciones de escherichia coli y métodos de estas
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
PH12015000376A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
BR112022004488A2 (pt) Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
AR109540A1 (es) Moléculas promotoras para expresar antígenos virales
CO2019012289A2 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar